Among other genetic alterations, mutations in the isocitrate dehydrogenase 2 enzyme gene (IDH2) have been linked to distinctive gene expression patterns and epigenetic changes among AML patients; they have also been associated with specific clinical outcomes [19]. This evidence concerns the gene IDH2 and acute myeloid leukemia.